Keywords: Renovo, Shire, Juvista, Scar revision surgery

Renovo shares plummet 75% as scar revision product Juvista fails to meet study endpoints

Article | 14 February 2011

Shares of UK-based biopharmaceutical firm Renovo (LSE: RNVO) plunged 75.1% to 17 pence last Friday, after the company announced that its first ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Renovo

Shire

Go to company listing

Related Drugs

Juvista

Go to drug listing